Sign in with Google
bullish
Imugene (IMU AU): Got US Patent for Oncolytic Virotherapy- A Crucial Step Forward for US Entry
327 Views19 Jul 2023 10:39
SUMMARY
- Imugene Ltd (IMU AU) got US patent for its oncolytic virotherapy CF33 products, including VAXINIA and CHECKVacc. The patent protects the method of composition and use of CF33 until 2037.
- Imugene has appointed two-decade experienced Dr Ron Weitzman as Interim Chief Medical Officer. Dr Weitzman’s expertise in solid-tumor and hematologic malignancies is of particular interest for Imugene.
- Imugene is actively recruiting patients for its five ongoing clinical trials. The company has a strong balance sheet holding more than A$150 million in cash, providing a runway through 2025.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- East Buy Holdings (1797 HK): Potential KWEB Deletion in June
- [Japan Activism] ISS Comes Out Supporting Orbis Against Tsuruha/Welcia Merger Ratio
- [Japan M&A] NTT (9432) Overpays To Buy Out NTT Data (9613) Minorities
- Laopu Gold (6181 HK): Heritage Luxury, Guochao Appeal. Key Facts, Financials & Valuation
- StubWorld: Geely Is (Mostly) Trading "Rich"; And May Still Bump Zeekr Terms
Top Unpaywalled Insights
More »- The Polycrisis Era (2025–2028): Navigating a World of Overlapping Disruptions
- Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
- India-UK Free Trade Agreement: A New Era for India's Textile Industry
- The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
- New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Imugene (IMU AU): Pipeline Progresses; Capital Injection to Extend Cash Runway to Late 202513 Jan 2025
- Imugene (IMU AU) Placement: Extended Runway for Clinical Programs Pipeline at Modest Equity Dilution18 Sep 2022
- Imugene (IMU AU): Clinical Trial Continued to Advance; Cash Position Still Strong25 Aug 2022
- Imugene (IMU AU): Promising Pipeline And Financial Muscle Power Are Biggest Strengths24 May 2022
x